Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
Virchows Arch. 2011 Oct;459(4):441-7. doi: 10.1007/s00428-011-1128-4. Epub 2011 Jul 20.
TMPRSS2-ERG, the most common gene fusion in prostate cancer, is associated with expression of a truncated protein product of the oncogene ERG. A novel anti-ERG monoclonal antibody has been recently characterized. We investigated the correlation between ERG rearrangement assessed by fluorescence in situ hybridization (FISH) and ERG expression detected by immunohistochemistry in a large cohort of patients treated with radical prostatectomy for clinically localized prostate cancer. Thirteen tissue microarrays comprising 305 tumors and a subset of 112 samples of nonneoplastic prostatic tissue were assessed for ERG rearrangement status by FISH and for ERG expression by immunohistochemistry. Accuracy of ERG detection by immunohistochemistry in predicting ERG status as assessed by FISH (criterion standard) was calculated in terms of sensitivity, specificity, positive and negative predictive values. Of 305 tumor foci, 103 (34%) showed ERG rearrangement by FISH. ERG was detected by immunohistochemistry in 100 (33%) cases, 99 of which were FISH positive. ERG detection by immunohistochemistry demonstrated a sensitivity and specificity of 96% and 99%, respectively, with positive and negative predictive values of 99% and 98%, respectively. None of the 112 samples of nonneoplastic prostatic tissue was rearranged by FISH or showed any ERG expression. In conclusion, ERG detection by immunohistochemistry in prostate cancer was highly predictive of ERG rearrangement as assessed by FISH in a large cohort of prostatectomy patients. Given the high yield and the easier task of performing immunohistochemistry vs. FISH, ERG assessment by immunohistochemistry may be useful for characterizing ERG status in prostate cancer.
TMPRSS2-ERG 是前列腺癌中最常见的基因融合，与致癌基因 ERG 截断蛋白产物的表达相关。最近，一种新型的抗 ERG 单克隆抗体已被描述。我们研究了在接受根治性前列腺切除术治疗的局限性前列腺癌患者的大样本中，荧光原位杂交（FISH）评估的 ERG 重排与免疫组织化学检测的 ERG 表达之间的相关性。使用 FISH 评估了 13 个组织微阵列（包含 305 个肿瘤）和非肿瘤前列腺组织的亚组 112 个样本的 ERG 重排状态，并通过免疫组织化学检测 ERG 表达。通过免疫组织化学检测 ERG 表达预测 FISH（金标准）评估的 ERG 状态的准确性，以灵敏度、特异性、阳性和阴性预测值来计算。在 305 个肿瘤灶中，有 103 个（34%）通过 FISH 显示 ERG 重排。100 个（33%）病例通过免疫组织化学检测到 ERG，其中 99 个为 FISH 阳性。免疫组织化学检测 ERG 的灵敏度和特异性分别为 96%和 99%，阳性和阴性预测值分别为 99%和 98%。112 个非肿瘤前列腺组织样本均未通过 FISH 重排或显示任何 ERG 表达。总之，在接受根治性前列腺切除术的前列腺癌患者的大样本中，免疫组织化学检测 ERG 高度预测了 FISH 评估的 ERG 重排。鉴于免疫组织化学检测的高产量和比 FISH 更容易执行的任务，免疫组织化学检测 ERG 可能有助于描述前列腺癌中的 ERG 状态。
